Navigation Links
Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal

WINNIPEG, Manitoba - (May 31, 2007) Medicure Inc. (TSX:MPH; Amex:MCU), a cardiovascular focused biopharmaceutical company, today announced that the results from its Phase 2 MEND-CABG trial are featured in a peer reviewed article in the June edition of The Journal of Thoracic and Cardiovascular Surgery, published by the American Association of Thoracic Surgery.

The article, titled, "Effects of pyridoxal-5-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: Results of the MEND-CABG randomized study", outlines evidence of MC-1's potential efficacy in reducing ischemic reperfusion injury. Additionally, the article presents further detail, background information and analysis of Medicure's positive MEND-CABG study.

"We are pleased that our novel cardioprotective product MC-1 is being recognized by one of the leading cardiovascular surgery journals," stated Medicure's President and CEO, Albert D. Friesen, PhD. "The results from MEND-CABG clearly show that patients treated with MC-1 experienced clinically meaningful reductions in the composite endpoint, driven by a pronounced reduction in large non-fatal myocardial infarctions, which comprise the majority of events after CABG surgery. We eagerly anticipate the results of the ongoing pivotal Phase 3 MEND-CABG II registration trial."

Additional Clinical Data

The article also includes new data from a post-hoc analysis demonstrating a statistically significant lower incidence of atrial fibrillation in the MC-1 groups (250 mg @.7% and 750 mg @.0%) compared to the placebo group (11.9%) between post operative day (POD) four and the end of the trial.

"Atrial fibrillation is one of the most common complications after CABG surgery, and is associated with a significant increase in morbidity and mortality, as well as prolonged hospital stay and increased hospital costs," commented Dr. Friesen. "Prevention of atrial fibrilla tion therefore would have a significant positive impact on patients undergoing CABG surgery. Given the limited success of prophylactic drug therapy for atrial fibrillation, the beneficial effects of MC-1 are promising and warrant further evaluation in future studies."


The MEND-CABG trial, completed in 2006, was a Phase 2 study involving 901 patients that evaluated MC-1 versus placebo in individuals undergoing CABG surgery at 42 investigational sites throughout Canada and the United States.

The 250 mg dose of MC-1 had a 37.2% reduction in the composite of cardiovascular death, non-fatal myocardial infarction (peak CK-MB ?100ng/ml), and non-fatal stroke versus placebo (p@028).

The reduction in the composite endpoint was driven by a significant 46.9% decrease in the incidence of non-fatal myocardial infarction (peak CK-MB ?100ng/ml) with the 250 mg dose of MC-1 versus placebo (p@008).

The clinical results reported at POD 30 were maintained throughout the 90 day follow-up period (POD 90). Safety analysis included in the MEND-CABG study demonstrated that MC-1 was well tolerated. No safety concerns were identified; the incidence of adverse events in the study was comparable across both treatment and control groups.

The MEND-CABG trial was the catalyst to Medicure's ongoing Phase 3 MEND-CABG II study.


The Phase 3 MEND-CABG II is a double-blind, randomized, placebo-controlled clinical trial that will enroll up to 3,000 patients undergoing CABG surgery at approximately 120 cardiac surgical centers throughout North America and Europe. Study patients will be randomized to receive placebo or MC-1 250 mg prior to surgery and for 30 days post operatively (POD 30). The primary efficacy endpoint of MEND-CABG II is the reduction in the composite of cardiovascular death and non-fatal myocardial infarction up to POD 30. Study patients will be followed for 60 days after treatment (90 days post op eratively) for additional safety and efficacy analysis. Study enrollment was initiated in November 2006.

The study protocol and entry criteria for MEND-CABG II closely follow that of the Phase 2 MEND-CABG study.

About MC-1

MC-1 is a novel cardioprotective compound that is being evaluated in the prevention of cardiac damage. Medicure has completed two Phase 2 studies with MC-1 demonstrating its cardioprotective effects. MC-1 has received a Fast Track Designation from the FDA as a treatment to reduce cardiovascular events associated with ischemic and/or ischemic reperfusion injury in patients experiencing percutaneous coronary interventions, coronary artery bypass graft surgery and acute coronary syndrome (ACS). Medicure intends to develop MC-1 for the CABG surgery and ACS markets, which have a combined annual incidence of approximately two million in the United States.

About Medicure Inc.

Medicure is a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders. The Company's solid position in this field is highlighted by the following:

* Lead compound MC-1 in pivotal Phase 3 study for FDA approval * Four positive Phase 2 trials completed with MC-1 * FDA Fast Track designation for MC-1 * U.S. rights to AGGRASTATR Injection (tirofiban hydrochloride) * Combination of MC-1 and lisinopril (MC-4232) completed Phase 2 * Dual action antithrombotic, MC-45308, with positive preclinical results

Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies.

This press release contains forward-looking statements, as defined under applicable securities legislation, that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking stat ements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise except as required by law. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the Company's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence on collaborative partners and the ability to meet its debt obligations. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of its Form 20F for the year ended May 31, 2006.

For more information, please contact:

Derek Reimer Adam Peeler

Chief Financial Officer Manager of Investor & Public Relations

Tel. 888-435-2220

Fax 204-488-9823


Web: <>


Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
(Date:10/12/2015)... COSTA MESA, Calif. , Oct. 12, 2015 ... reaffirmed the accreditation of Harbor Compounding Pharmacy in ... accreditation is awarded in recognition of the pharmacy,s ... --> ... --> ...
(Date:10/12/2015)... Calif. , Oct. 12, 2015 /PRNewswire/ ... and Chief Scientific Officer of Asterias Biotherapeutics, ... company in the emerging field of regenerative ... webcast, sponsored in part by Asterias Biotherapeutics, ... Lebkowski will discuss the progress to date ...
(Date:10/12/2015)... , Oct. 12, 2015  In a Sutter ... the Journal of Neurology, Neurosurgery, and Psychiatry, the blood ... brain atrophy and cognitive decline in patients in the ... --> --> IVIG, extracted from the ... to amyloid, an abnormal brain protein found in patients ...
Breaking Medicine Technology:
(Date:10/12/2015)... , ... October 12, 2015 , ... ... teams up with the Cleveland Clinic in honor of Breast Cancer Awareness Month. ... Sunset Pink color, AcousticSheep will donate a SleepPhones® Classic product to a breast ...
(Date:10/12/2015)... ... October 12, 2015 , ... Advera Health Analytics, Inc ... to qualified Managed Care Organizations (MCOs) in order to provide health plans, payers, systems, ... decision making process. In addition, the DSM is also being offered to healthcare media ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... On July ... MN. Their mission: To paddle the entire 2,320-miles of river to the Gulf of ... halfway done with the monumental journey, with two months remaining for a November 22nd ...
(Date:10/12/2015)... PA (PRWEB) , ... October 12, 2015 , ... A ... are labeled as “child safe.” An inventor from Rutland, Mass., has modified a conventional ... V NOSE SUCKER to use in withdrawing mucus from sinuses and nasal passages more ...
(Date:10/12/2015)... Clara, CA (PRWEB) , ... October 12, 2015 , ... Santa Clara dentist , ... hygiene with the information provided by the ADHA white paper announcement. , “I want each ... them to have the best possible smile,” states Santa Clara dental implants dentist , ...
Breaking Medicine News(10 mins):